neutral
14h agoCorona Remedies delivers strong listing pop as investor demand stays elevated
Corona Remedies made a strong debut on Dalal Street, listing at a 38.42 percent premium over its IPO price of ₹1,062 and trading above ₹1,470 on both NSE and BSE during early hours. The ₹655 crore offer for sale issue saw heavy oversubscription across investor categories, reflecting confidence in the company’s steady profitability, strong return ratios, and focused presence in chronic therapy segments.
Explore:Mutual Fund Themes
neutral
14h agoCorona Remedies delivers strong listing pop as investor demand stays elevated
Corona Remedies made a strong debut on Dalal Street, listing at a 38.42 percent premium over its IPO price of ₹1,062 and trading above ₹1,470 on both NSE and BSE during early hours. The ₹655 crore offer for sale issue saw heavy oversubscription across investor categories, reflecting confidence in the company’s steady profitability, strong return ratios, and focused presence in chronic therapy segments.
Explore:Mutual Fund Themes
1 min read
63 words
Corona Remedies listed at a sharp premium after strong IPO demand, as investors backed its profitable growth profile, high return ratios, and leadership in key pharmaceutical therapy areas.
Corona Remedies made a strong debut on Dalal Street, listing at a 38.42 percent premium over its IPO price of ₹1,062 and trading above ₹1,470 on both NSE and BSE during early hours. The ₹655 crore offer for sale issue saw heavy oversubscription across investor categories, reflecting confidence in the company’s steady profitability, strong return ratios, and focused presence in chronic therapy segments.
Corona Remedies made a strong debut on Dalal Street, listing at a 38.42 percent premium over its IPO price of ₹1,062 and trading above ₹1,470 on both NSE and BSE during early hours. The ₹655 crore offer for sale issue saw heavy oversubscription across investor categories, reflecting confidence in the company’s steady profitability, strong return ratios, and focused presence in chronic therapy segments.
Dec 15, 2025 • 07:50